Olema Pharmaceuticals, Inc. beat EPS estimates 62% of the time across 16 reported quarters (10 beats, 6 misses), averaging +3.5% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.53 | $-0.61 | -15.1% | Miss | |
| Q1 FY26 | $-0.52 | $-0.52 | +0.0% | Beat | |
| Q4 FY25 | $-0.51 | $-0.50 | +2.0% | Beat | |
| Q3 FY25 | $-0.44 | $-0.49 | -11.4% | Miss | |
| Q2 FY25 | $-0.43 | $-0.51 | -18.6% | Miss | |
| Q1 FY25 | $-0.49 | $-0.36 | +26.5% | Beat | |
| Q4 FY24 | $-0.63 | $-0.51 | +19.1% | Beat | |
| Q3 FY24 | $-0.59 | $-0.60 | -1.7% | Miss | |
| Q2 FY24 | $-0.54 | $-0.54 | +0.0% | Beat | |
| Q1 FY24 | $-0.53 | $-0.56 | -5.7% | Miss | |
| Q4 FY23 | $-0.49 | $-0.49 | +0.0% | Beat | |
| Q3 FY23 | $-0.51 | $-0.48 | +5.9% | Beat |
Back to OLMA overview · OLMA holders · OLMA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.